Enhanced dermal and retinal vascular permeability in streptozotocin-induced type 1 diabetes in Wistar rats: Blockade with a selective bradykinin B 1 receptor antagonist

Regulatory Peptides

Volumn 124, Issue 1-3, 2005, Pages 221-224

  Lawson, Sibi R ^a   Gabra, Bichoy H ^a   Guérin, Brigitte ^a,b   Neugebauer, Witold ^a,b   Nantel, François ^b   Battistini, Bruno ^b   Sirois, Pierre ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b IPS Pharma Inc   (Canada)

Author keywords

Bradykinin B 1 receptor; Retina; Skin; Type 1 diabetes; Vascular permeability

Indexed keywords

BRADYKININ B1 RECEPTOR ANTAGONIST; R 954; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; INHIBITION KINETICS; NONHUMAN; PRIORITY JOURNAL; RAT; RETINA; SKIN PERMEABILITY; STREPTOZOCIN DIABETES;

ANIMALS; CAPILLARY PERMEABILITY; DIABETES MELLITUS, TYPE 1; MALE; RATS; RATS, WISTAR; RECEPTOR, BRADYKININ B1; RETINA; SKIN; STREPTOZOCIN;

RATTUS NORVEGICUS;

EID: 8444226815     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2004.09.002     Document Type: Article

References (21)

1. C.F. Steil Diabetes mellitus J.T. Diprio R.L. Talbert G.C. Yee G.R. Matzke B.G. Weels L.M. Posey Pharmacotherapy: a pathophysiological approach 1999 Appleton and Lange Stamfort (CT) 1219 1243
2. K. Auckland, and R.K. Reed Interstitial-lymphatic mechanisms in the control of extracellular fluid volume Physiol. Rev. 73 1993 1 78
3. D. Regoli, and J. Barabé Pharmacology of bradykinin and related kinins Pharmacol. Rev. 32 1980 1 46
4. 1 receptor: a review Immunopharmacology 30 1995 1 26
5. R. Couture, M. Harrisson, R.M. Vianna, and F. Cloutier Kinin receptors in pain and inflammation Eur. J. Pharmacol. 429 2001 161 176
6. A. Rabinovitch An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus Diabetes Metab. Rev. 14 1998 129 151
7. K.K. Yerneni, W. Bai, B.V. Khan, R.M. Medford, and R. Natarajan Hyperglycemia-induced activation of nuclear transcription factor kappa B in vascular smooth muscle cells Diabetes 48 1999 855 864
8. E. Schremmer-Danninger, A. Hermann, E. Fink, H. Fritz, and A.A. Roscher Identification and occurrence of mRNA for components of the kallikrein-kinin system in human skin and in skin diseases Immunopharmacology 43 1999 287 291
9. 2 antagonists and bradykinin-induced blood flow in rat skin inflammation Inflamm. Res. 51 2002 295 299
10. J.X. Ma, Q. Song, H.C. Hatcher, R.K. Crouch, L. Chao, and J. Chao Expression and cellular localization of the kallikrein-kinin system in human ocular tissues Exp. Eye Res. 63 1996 19 26
11. H. Takeda, Y. Kimura, H. Higashida, and S. Yokoyama Localization of B2 bradykinin receptor mRNA in the rat retina and sclerocornea Immunopharmacology 45 1999 51 55
12. N. Aronin, S.E. Leeman, and R.S. Clements Diminished flare response in neuropathic patients: comparison of effects of substance P, histamine and capsaicin Diabetes 36 1987 1139 1143
13. 1 receptors in the retinal microvessels of the streptozotocin-diabetic rat Br. J. Pharmacol. 140 2003 33 40
14. 1 receptor antagonists with multi-enzymatic resistance properties Can. J. Physiol. Pharm. 80 2002 287 292
15. M. Chakir, and G.E. Plante Endothelial dysfunction in diabetes mellitus Prostaglandins Leukot. Essent. Fat. Acids 54 1996 45 51
16. B. Simard, B.H. Gabra, and P. Sirois Inhibitory effect of a novel bradykinin receptor B1 receptor antagonist, R-954, on enhanced vascular permeability in type 1 diabetic mice Can. J. Physiol. Pharm. 80 2002 1203 1207
17. K.J. Escott, and S.D. Brain Effect of a calcitonin gene-related peptide antagonist (CGRP8-37) on skin vasodilatation and oedema induced by stimulation of the rat saphenous nerve Br. J. Pharmacol. 110 1993 772 776
18. M. Takeda, F. Mori, A. Yoshida, A. Takamiya, S. Nakagomi, and E. Sato Constitutive nitric oxide synthase is associated with retinal vascular permeability in early diabetic rats Diabetologia 44 2001 1043 1050
19. S.P. Ayalasomayajula, and U.B. Kompella Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model Eur. J. Pharmacol. 458 2003 283 289
20. 2 kinin receptor antagonists in diabetic mice Can. J. Physiol. Pharm. 74 1996 586 589
21. A. Zuccollo, M. Navarro, M. Frontera, F. Cueva, M. Carattino, and O. Catanzaro The involvement of kallikrein-kinin system in diabetes type I (insulitis) Immunopharmacology 45 1999 69 74